Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.27B
Revenue (ttm)	1.07B
Net Income (ttm)	621.98M
Shares Out	n/a
EPS (ttm)	0.81
PE Ratio	8.47
Forward PE	n/a
Dividend	0.23 (7.84%)
Ex-Dividend Date	Jun 25, 2025

Volume	136,800
Average Volume	160,060
Open	2.890
Previous Close	2.890
Day's Range	2.860 - 2.900
52-Week Range	1.990 - 3.130
Beta	n/a
RSI	48.40
Earnings Date	Oct 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY